

MAUNA KEA TECHNOLOGIES APPOINTS MARIE-LAURE POCHON TO BOARD OF DIRECTORS

PARIS, June 28, 2012 - Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the endomicroscopy market, announced today that Marie-Laure Pochon has been appointed to the company's Board of Directors.

Mrs. Pochon has spent her entire career in the healthcare industry, most recently serving as Executive Vice President of Commercial Operations at H. Lundbeck A/S where she was previously Chief Executive of Lundbeck France and Regional Vice President for France, Belgium, UK, Spain, Italy, Turkey & Germany. Prior to joining Lundbeck's French division in 2007, she served as President of Schwarz Pharma France. She started her career at Merck Sharp & Dohme (MSD) where she held roles of increasing responsibility for 12 years, followed by four years at Pfizer Inc. Pochon, 53 years old, graduated from Ecole Supérieure de Physique et Chimie de Paris (Higher School of Physics and Chemistry of Paris) and received a Masters in Business Administration from Institut Supérieur des Affaires (ISA) in association with HEC Paris.

Mrs. Pochon has been designated by Creadev to fill its second seat on the Board following the resignation of Mr. Nicholas Mulliez in March 2012. The company's shareholders have approved her nomination for a three-year term, until the 2015 Annual Meeting of Shareholders.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and help detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio[®], a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information about Mauna Kea Technologies, go to www.maunakeatech.com

United States

Lazar Partners Ltd.

Erich Sandoval

Tel: +1 917 497 2867

esandoval@lazarpartners.com

France et Europe

ALIZE RP

Caroline Carmagnol

Tel: +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59

caroline@alizerp.com

Mauna Kea Technologies

Alexander Bryson

Marketing Communications and Brand
Manager

Tel: +33 (0) 1 70 08 09 92

alexander@maunakeatech.com

NewCap.

Investor Relations and Financial Communications

Pierre Laurent / Florent Alba

Tel: +33(0)1 44 71 94 94

maunakea@newcap.fr